A founder who built a food-delivery empire has stepped into a quieter arena, wearing an unreleased device near his temple that he hopes will one day read the flow of blood through the brain. When a radiologist dismissed it as a toy without scientific standing, the exchange became a familiar human scene: a bold inventor asking for patience, and a clinician asking for proof. Both impulses are old, and both are needed, and the outcome of this small quarrel will depend on whether the device ever leaves the prototype stage to face the evidence it has not yet been asked to show.
Goyal Defends Unreleased 'Temple' Wearable as AIIMS Doctor Calls It a 'Toy'
Months away from a public preview, "if at all"
Mark
Why did a clip on someone's temple become such a big story?
Mimi
Because of who was wearing it. Goyal runs Zomato, and he wore it on a popular podcast. People wanted to know what it was, and when he said it measured brain flow, doctors wanted to see evidence.
Luke
And so far there's none public. Goyal himself says no benchmarking data has been released. Whatever Temple measures is his claim, not an established result.
Mark
Dr. Datta called it a toy with zero scientific standing. Is that a verdict on the device?
Luke
It's one radiologist's judgment, and it's aimed at a product nobody can test yet. It's fair to say the evidence is missing. It's less clear anyone has shown the device fails.
Mimi
Goyal's point is that it isn't for sale, so there's nothing to warn buyers about. He says the data will come if it's sold.
Mark
What about the neurologist's suggestion?
Mimi
Dr. Sudhir Kumar of Apollo Hospitals in Hyderabad suggested the internal carotid artery in the neck instead of the temporal artery, since that's likelier to track cerebral blood flow. It was engagement, not just criticism.
Luke
Worth noting that it also implies the current placement may not be ideal. Goyal acknowledged it but didn't say he'd change anything.
Mark
And the Bryan Johnson comparison?
Mimi
Goyal rejected it flatly, saying they need to be their own original selves.
Luke
He also said preview devices are months away, if at all. So even the timeline is uncertain.
Il Polso
- A podcast appearance with a clip-like device on his temple ignited a public argument before the product even had a name.
- AIIMS radiologist Dr. Datta called Temple a 'toy' with 'zero scientific standing,' and the debate quickly shifted from curiosity to credibility.
- Goyal pushed back on X, insisting Temple is a personal research prototype with no public benchmarking data and no pre-orders.
- A neurologist at Apollo Hospitals offered a technical correction on sensor placement, and Goyal answered with lighthearted emojis.
- Temple sits months from any public preview and may never be sold, so whether it measures what its creator claims remains unresolved.
A founder who built a food-delivery empire has stepped into a quieter arena, wearing an unreleased device near his temple that he hopes will one day read the flow of blood through the brain. When a radiologist dismissed it as a toy without scientific standing, the exchange became a familiar human scene: a bold inventor asking for patience, and a clinician asking for proof. Both impulses are old, and both are needed, and the outcome of this small quarrel will depend on whether the device ever leaves the prototype stage to face the evidence it has not yet been asked to show.
Deepinder Goyal, the founder and chief executive of Zomato, was recorded on a podcast with entrepreneur Raj Shamani wearing a small metallic device clipped near his temple. That single image was enough to start a public argument about whether an unreleased gadget with no published data deserves attention at all.
Goyal later named the device Temple and described it as an early prototype meant to measure brain flow in real time. He placed it within his own personal research into longevity and was firm that it is not a Zomato consumer product.
The sharpest response came from Dr. Datta, a radiologist at AIIMS Delhi, who said Temple had zero scientific standing, offered no clinical evidence of usefulness, and was a toy. His remarks spread quickly and turned the conversation from fascination toward doubt.
Goyal replied on X that no commercial announcement had been made and no official benchmarking had been released. Much of the work is still underway, and preview devices are months away from reaching anyone, if they reach anyone at all. He found it strange that people were warning against buying something that could not be ordered, and he promised to share scientific data if the device is ever sold.
Not every reply was dismissive. Dr. Sudhir Kumar, a neurologist at Apollo Hospitals in Hyderabad, suggested placing the sensor over the internal carotid artery rather than the superficial temporal artery, since that vessel better tracks cerebral blood flow. Goyal took the advice lightly, answering with emojis.
For now Temple remains a prototype without a release date, and the question of whether it measures what its creator says is still open.
Deepinder Goyal, the founder and chief executive of Zomato, sat for a podcast with entrepreneur Raj Shamani wearing a small metallic, clip-like device near his temple. That detail set off a public argument about whether a wearable that has not been released, and has published no data, deserves to be taken seriously.
Goyal later said the device was called Temple. He described it as an early-stage prototype meant to measure "brain flow" in real time. He framed it as part of his own research into human longevity, and was clear that it is not a Zomato consumer product.
The sharpest reaction came from Dr. Datta, a radiologist at AIIMS Delhi. He said Temple had "zero scientific standing" and that there was no clinical data to show it was useful. He also called it a "toy." His remarks spread online and moved the conversation away from curiosity about the gadget and toward questions of credibility.
Goyal answered on X. He said Zomato had made no public commercial announcement about Temple and had released no official device benchmarking data. Much of the work, he wrote, is still underway, and the team is months away from putting preview devices in public hands, "if at all."
He also pointed to what he found odd about the criticism. In his telling, people were advising the public not to buy an "unvalidated" device that cannot yet be ordered or even pre-ordered. He called the situation "funny." He promised that scientific data would be shared if and when Temple is sold, and urged skeptics to "be curious, and cheer Indian startups."
Not all of the responses were dismissive. Dr. Sudhir Kumar, a neurologist at Apollo Hospitals in Hyderabad, offered a technical suggestion. He advised Goyal to position the device over the internal carotid artery in the neck rather than the superficial temporal artery, arguing that blood flow in the internal carotid is more likely to correlate with cerebral blood flow. Goyal acknowledged the advice but kept his tone light, even replying with emojis.
Other users compared Temple with the experiments of biohacker Bryan Johnson. Goyal rejected that, writing, "No we don't. We need to be our own original selves." One more user suggested a more practical wearable, one that would measure blood pressure, which pointed to public appetite for everyday health tools.
For now, Temple remains an unreleased prototype, months from any public preview and possibly never offered for sale. Doctors want validation, and Goyal has said data will come only if the device is sold, so the question of whether it measures what he says it does is still open.
Citazioni salienti
We haven't released any official device benchmarking data. We're months away from introducing preview devices to the public, if at all.— Deepinder Goyal, on X
Temple has zero scientific standing and lacks clinical data.— Dr. Datta, radiologist, AIIMS Delhi
Vuoi la storia completa?
Leggi l'originale su Republic World ↗
Health & Medicine